Last reviewed · How we verify
Chronic idiopathic neutropenia
Approved treatments
- Neupogen · University of Chicago
- Neupogen · Amgen
Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic idiopathic neutropenia patent landscape — cliff calendar, originator estates, attackable patents
- Chronic idiopathic neutropenia treatment landscape brief
- Chronic idiopathic neutropenia treatment updates RSS
Frequently asked questions about Chronic idiopathic neutropenia
What drugs treat Chronic idiopathic neutropenia?
Tracked treatments include Neupogen.
What is the treatment for Chronic idiopathic neutropenia?
Standard treatment for Chronic idiopathic neutropenia includes Neupogen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic idiopathic neutropenia patent cliff · Chronic idiopathic neutropenia CI report
- Treatment: Neupogen · University of Chicago
- Treatment: Neupogen · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing